Pardes Biosciences, Inc. (PRDS) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Carlsbad, CA, 美国. 現任CEO為 Thomas G. Wiggans.
PRDS 擁有 IPO日期為 2021-12-27, 57 名全職員工, 在 NASDAQ Global Market, 市值為 $135.19M.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
